# Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM

> **NCT02112175** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 46 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT02112175
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-30
- **Primary completion:** 2020-10-12
- **Final completion:** 2020-10-12
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2021-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02112175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02112175, "Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02112175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*